Healthcare & Pharmaceuticals

The algorithms that make social media addictive have become powerful mechanisms for drug dealers
Two years ago, when companies received a big tax break to bring home their offshore profits, the president and Congress justified it as a one-time tax amnesty that would create American jobs. Drug makers were the biggest beneficiaries of the amnesty program, repatriating about $100 billion in foreign profits and paying only minimal taxes. But the companies did not create many jobs in return. Instead, since 2005 the American drug industry has laid off tens of thousands of workers in thi
Johnson & Johnson has been sued by over 1,200 women who blame the company's talcum powder products for their ovarian cancer. Not only are U.S. courts beginning to agree with them, juries have started to award victims millions of dollars in compensation.
Privatization of major medical laboratories from the National Hospital Service (NHS) in Britain has led to a dramatic decline in service quality, according to a "Transforming Pathology, the Serco way," a recent report from UK-based researchers Corporate Watch.
While 25 million Africans are living with AIDS, Northern pharmaceutical companies and governments are turning their back on the greatest tragedy of our time according to former deputy head of UNICEF.
In the final hectic days before Congress adjourns for the year, lobbyists are swarming around the Capitol, trying to adorn a bill on bioterrorism with all sorts of special-interest provisions.
The Kazipally industrial area - once good farm country - now accounts for more than one-third of India's pharmaceutical industry, meaning skyrocketing rates of cancer, heart disease and birth defects for its residents.
U.S. corporations gave away $18.15 billion in charitable donations in 2012 - a combination of cash, grants, and in-kind goods - up 12.2 percent in nominal terms over the previous year. A closer look reveals profit motives, notably for pharmaceutical companies and retail chain Wal-Mart.
A Swiss drug company, Novartis, will go before the Indian Supreme Court this monnth to fight patent laws that protect the global supply of inexpensive medicines to treat AIDS, cancer and other diseases. The lawsuit - which involves a drug called Gleevec - is being opposed by international aid groups.